JP5361527B2 - Anemia treatment - Google Patents

Description

  The present invention relates to a therapeutic agent for anemia comprising a component derived from an elm flower part and a component derived from a leaf part of a urushi.

  Researches for developing pharmaceutical compositions using components obtained from plants growing in nature have been actively conducted. Among plants existing in nature, those that humans and non-human animals use as foods are particularly active because they are low in toxicity and easy to obtain. Up to now, various pharmaceutical compositions have been developed, and the types are extremely large.

  Elm and urushi which the inventor has paid attention to are plants that grow abundantly in nature, and are easily available. However, elm has hardly been studied as a pharmaceutical until now. Urushi is also known to have urushiol which is toxic and causes dermatitis when attached to the skin, and has a strong impression that it has a bad effect on the human body. For this reason, there were few attempts to use elm and urushi as medicines compared to other plants. Under such circumstances, it has been found that a composition combining elm and urushi has high reverse transcriptase inhibitory activity (see Patent Document 1). It has also been found that a composition combining elm and urushi is useful for the prevention or treatment of hypercholesterolemia, arteriosclerosis and liver dysfunction (see Patent Document 2). However, no investigation has been made on physiological activities other than these, and no knowledge has been obtained about the effect of the composition combining elm and urushi on anemia.

  On the other hand, anemia caused by the fact that the number of red blood cells in the blood is less than the reference value is a familiar symptom that often appears in women. For this reason, research for developing an anemia treatment agent has been conducted in various fields, and various compounds and compositions having an anemia-improving action have been provided so far (see, for example, Patent Documents 3 to 7).

JP-A-11-130688 (see 0047) JP 2001-354581 A (refer to 0045 to 0053) JP-A-8-208661 Japanese Patent Laid-Open No. 2002-20296 JP 2002-255832 A JP 2003-48830 A JP 2008-50277 A

  However, conventionally proposed anemia treatment agents have problems such as complicated methods for synthesizing active compounds and methods for obtaining active compositions, and low toxicity has not been sufficiently confirmed. There are many things. In addition, there are many cases where it is difficult to take because of a high iron content, or there are concerns about adverse effects due to a rapid increase in iron concentration in the living body. For this reason, it is necessary to develop a new therapeutic agent for anemia. Therefore, the present inventors have intensively studied for the purpose of providing a new therapeutic agent for anemia that can be produced by a simple method and has low toxicity.

  As a result of intensive studies to solve the above-mentioned problems, the present inventors have an anemia-improving action excellent in a composition containing a component derived from an elm flower part and a component derived from a leaf part of a sea urchin. Has been found to provide the present invention.

  That is, the present invention provides a therapeutic agent for anemia comprising an elm flower part or an extract thereof and a leaf part of an urushi or an extract thereof.

  The elm used for the anemia treatment agent of the present invention preferably belongs to Ulmus hollandica, and among them, wegataa (Vegeta), comelin (Commelin), Gronveid (Belgica), Kurusius (Clusius) Preferably, those selected from the group consisting of Columella, Dodoens and Homestead, particularly those selected from the group consisting of Vegeta, Comelin and Groenveid. preferable. The agent for treating anemia of the present invention may contain a powder obtained by drying elm flower parts and a powder obtained by drying leaf parts of an urushi, or an extract of elm flower parts and an extract of an urushi leaf part. The thing may be included.

  Further, the present invention is that (1) an elm flower part or an extract thereof and (2) a leaf part of an urushi or an extract thereof are included in any of a plurality of compositions constituting the kit. A featured anemia treatment kit is also provided.

  Furthermore, the present invention also provides a method for treating anemia, comprising administering a composition comprising an elm flower or an extract thereof and a leaf of an urushi or an extract thereof.

  The composition of the present invention comprising an elm flower part or an extract thereof and a leaf part of an urushi or an extract thereof has an anemia improving action. Moreover, the composition of this invention can be manufactured by a simple method, and its toxicity is low.

  Hereinafter, the therapeutic agent for anemia of the present invention will be described in detail. The description of the constituent elements described below may be made based on typical embodiments of the present invention, but the present invention is not limited to such embodiments. In the present specification, a numerical range represented by using “to” means a range including numerical values described before and after “to” as a lower limit value and an upper limit value.

The therapeutic agent for anemia of the present invention comprises an elm flower part or an extract thereof, and a leaf part of an urushi or an extract thereof.
The type of elm used for the anemia treatment agent of the present invention is not particularly limited. Preferred is the use of elm belonging to Ulmus hollandica. Ulmus hollandica includes a hybrid of Ulmus carpinifola and Ulmus grabra, and is relatively large. In addition, the twig surface is generally smooth, and it is common that the fruit does not bear the center of the wing piece. Ulmus Hollanda is planted in Europe as street and park trees, and there are also horticultural varieties.

  Specific plant species belonging to Ulmus Hollanda include Vegeta, Commelin, Groenveid, Belgica, Cliusius, Columella, Dodoens and Dodoens. Elm such as Homestead) can be exemplified. Of these, Vegeta, Comelin, and Groenveid are particularly preferred.

  Wegetaa (Vegeta) is a very sturdy elm consisting of multiple main branches. The main branches of young trees tend to grow diagonally, but generally spread sideways as they grow. For this reason, there are many branches that are not united and extend in an arbitrary direction. The trunk has many long tears and is gray. Vegeta leaves are larger than Belgica leaves described below and flatter than Commelin leaves. The roots of the leaves are wide and the shapes are various, such as an inverted egg shape and an oval shape. The buds are generally large and shiny reddish brown. Wegetaa also includes Huntingdon elm.

  Commelin is a sturdy elm with an open canopy. Many trunks are relatively straight, with a slight spiral. Branches are sparse and thin compared to Vegeta. The color of branches is generally reddish brown. The crown is often visible from below. The leaves are generally light green and small, and the veins are generally bright. The florescence is sparse and leaves much later than Vegeta. Most of the leaves are oval and have short and sharp tips. Comelin is generally strong in the wind and slow in defoliation.

  Groenveid is a large and windy elm. The tree height is about 15 to 20 m, the apex is divided into a plurality, and the tree crown is generally in a thin and well-formed shape. The leaves are small and very dense, dark green but completely yellow in autumn. The back of the leaves has vellus hair and has a slightly dull color. Due to the slow growth, there are relatively many flowers and fruits. For this reason, there exists an advantage that the flower part required by this invention can be acquired in large quantities from one elm.

  Crusius is an elm with a well-shaped crown and strong wind resistance. Columella is an elm with a small tree. Dodoens is a sturdy elm that has dark green leaves and glossy branches. Homestead is an elm grown in the United States. Dodoens and Homestead are both similar to Wegeta.

The Ulmus hollandica used in the present invention includes a hybrid of Ulmus carpinifola and Ulmus grabra.
Ulmus carpinifola generally has a wide and elliptical tree shape with a tree height of about 25 to 30 m. The bark gets rougher with age. Many twigs are relatively thin and have no hair. In addition, depending on the species, a cork layer may be clearly formed on a shoot that grows quickly. The leaves have an inverted egg shape and are often smaller than 8 cm. There are about 12 pairs of veins on the left and right.
There are many kinds of elm belonging to Ulmus carpinifola, and examples thereof include Dampieri, Hoersholmiensis, Sarniensis, and Wuredei.

On the other hand, the Ulmus grabra is a large elm with a wide and round canopy. The roots are not well developed and the bark is gray and smooth at first, but later has shallow grooves. In general, thick brown limbs grow densely, and the skin of the crown part is pink. The leaves are 8 to 16 cm, and are more rough than Ulmus carpinifola. The petiole is short and generally has slanted leg legs covering the whole. The veins extending from side to side are 12 to 18 pairs, and the inflorescence is larger. In addition, the wing piece for flying seeds has an inverted egg shape and is actually in the center.
Specific examples of elm belonging to Ulmus grabra include Camperdownii, Exoniensis, and Horizontalis.

In the present invention, plant species and elm species belonging to Ulmus hollandica other than these specific examples can also be used.
In the present invention, plant species belonging to Ulmus hollandica and plant species obtained by crossing other elm species with other plant species can also be preferably used. Other plant species to be crossed may be other elm species or plant species other than elm. Further, the plant species to be mated may be only one type or a plurality of types. Further, a variety obtained by further mating a variety obtained by mating may be used. Thus, the therapeutic agents for anemia of the present invention include all those utilizing plant species derived from elm including Ulmus hollandica.

In the present invention, only one kind of these elm seeds may be used, or a plurality of kinds may be used in combination.
In the present invention, elm flower is used. For example, plant species derived from Ulmus hollandica are budd from winter to early spring and bloom in spring. The size of the flower bud may be small. For this reason, in this invention, it is preferable to acquire and use a flower part from the stage of a bud until a flower disperses.

The elm flower part can be used in a state that is easy to use as an anemia treatment agent. For example, it may be used by mixing it with a suitable component after making it into a strip or powder, or using an extract extracted with a suitable solvent.
When the flower part is cut into pieces or powder, the collected flower part may be processed as it is using a cutter, shredder, colloid mill, etc., but once dried, it is shredded and powdered. It is preferred to do so. The flower part is generally dried until the water content is less than 10% by weight, preferably less than 5% by weight, more preferably less than 3% by weight. Drying may be natural drying or mechanical drying. Moreover, when drying, it is preferable to carry out within 30 minutes after flower part collection.

  The drying temperature of the flower part is not particularly limited. Therefore, rapid heating and drying may be performed using a pressure drum heating device or electromagnetic waves. When using a pressure type drum heating device, it is preferable to heat and dry within the range of 80-140 degreeC. The drying time is usually within 2 minutes, preferably within 1 minute, more preferably about 40 to 50 seconds. Moreover, when using electromagnetic waves, such as a microwave oven, it can heat-dry for about 20 to 50 second at 600 W, for example. By heating and drying under such conditions, the activity of an undesirable enzyme contained in the flower part raw material can be suppressed or inactivated, and decomposition of the physiologically active component can be prevented to some extent.

  What was rapidly heated and dried may be used as it is, or may be used after further drying at a low temperature. When performing low temperature drying, it is preferable to carry out within the range of -5 degreeC-10 degreeC. The low temperature drying can be performed by using a hot air drying device such as a far infrared drying device, a ventilation drying device, an ice temperature drying device or the like alone or in combination. For example, after performing far infrared drying, it can be dried at ice temperature. By performing such low temperature drying, decomposition of the physiologically active ingredient can be prevented.

  The flower part can be shredded or pulverized using a device or tool suitable for the purpose. For example, it can be made into a powder of 50 to 100 μm using a colloid mill. Such shredding and pulverization may be performed before drying, after high-temperature drying, or after low-temperature drying.

  The flower part can be used as an extract as well as in the form of strips or powder in this way. The flower part to be extracted may be any of the collected flower part itself, a fragmented part of the collected flower part, a high-temperature dried part, a low-temperature dried part, and the like. In order to increase the extraction efficiency, it is preferable to fragment the flower part to some extent. The extraction solvent is preferably water or alcohol, but other extraction solvents can also be used. Examples of the alcohol solvent include methanol, ethanol, propanol, isopropanol, butanol, isobutanol, tert-butanol, pentanol, isopentanol, hexanol, isohexanol and the like. Any one of these solvents may be used or may be used in combination. For example, 30-50% ethyl alcohol or methyl alcohol aqueous solution can be used.

Extraction may be performed at room temperature or under reflux. An extraction device such as a Soxhlet extractor may also be used. Specifically, a method of extracting with a Soxhlet extractor for 30 to 60 minutes using a 50% aqueous ethanol solution at a reflux temperature can be exemplified.
The extracted extract may be used as it is as a therapeutic agent for anemia as it is, but it is preferable to concentrate and use it to enhance the effect. The degree of concentration varies depending on the use environment. Further, the solvent may be removed until it becomes powdery, and the concentration may be adjusted by further dissolving in physiological saline after making into powder. When using the therapeutic agent for anemia of the present invention as a liquid, the solid content is preferably 1 to 20% by weight, more preferably 2 to 15% by weight, and further preferably 3 to 13% by weight. Preferably, it is further more preferable that it is 5 to 10 weight%.

In the therapeutic agent for anemia of the present invention, a leaf portion of an urushi or an extract thereof is used together with an elm flower portion or an extract thereof.
Urushi used in the present invention can be selected from those belonging to the family Ursiaceae. Particularly preferred are leaves of plant species belonging to the genus Ursi. For example, urushi (Rhus vernicitula), yamaurushi (Rhus trichocarpa), shitaurushi (Rhus ambigna), null (Rhus javanica), yamahaze (Rhus sylvestris) can be illustrated. The urushi used is preferably a young leaf with soft leaves. In particular, those of 8 weeks or less are preferable, and those of 4 weeks or less are more preferable.

  These urushi leaf parts can be dried, powdered, chopped and extracted according to the above-mentioned method, like elm flower parts. Although the mixing ratio of the component derived from the elm flower part and the component derived from the leaf part of the urushi can be appropriately determined, it is generally within the range of 1: 0.1 to 10, preferably 1: 0.3 to 3. More preferably, it is a case where it mixes by the ratio of 1: 0.5-2.

  The composition of the present invention comprising an elm flower part or an extract thereof and a leaf part of an urushi or an extract thereof has an anemia improving action. An effective amount of the therapeutic agent for anemia of the present invention can be used to improve anemia symptoms by administering it to mammals including humans.

  The anemia therapeutic agent of the present invention is useful, for example, as a human anemia treatment agent or an anemia treatment agent for mammals other than humans. That is, it can be applied not only to humans but also to livestock and poultry such as pigs, cows and birds.

  The therapeutic agent for anemia of the present invention can be used in various forms depending on the purpose of use. The treatment of anemia as used in the present invention is a concept including anemia symptom progression inhibition and symptom improvement.

  For example, when the therapeutic agent for anemia of the present invention is used as a pharmaceutical product, various dosage forms can be selected depending on the administration route. The therapeutic agent for anemia of the present invention can be administered orally or parenterally. For example, rectal administration, intranasal administration, buccal administration, sublingual administration, intravaginal administration, intramuscular administration, subcutaneous administration, and intravenous administration can be performed. Among them, the therapeutic agent for anemia of the present invention is preferably administered orally, subcutaneously or transdermally, and particularly preferably administered orally.

  As preparations suitable for oral administration, tablets, capsules, powders, fine granules, granules, solutions, syrups and the like can be mentioned. As preparations suitable for parenteral administration, injections, drops, suppositories , Inhalants, transdermal absorbents, transmucosal absorbents, patches and the like. The injection may be used for any of intravenous injection, intramuscular injection, subcutaneous injection, infusion and the like. The therapeutic agent for anemia of the present invention is particularly preferably any of oral preparations, injections and patches.

  If necessary, pharmacologically and pharmaceutically acceptable additives can be added to the anemia therapeutic agent of the present invention. For example, excipients, disintegrants or disintegration aids, binders, lubricants, surfactants, coating agents, dyes, diluents, bases, solubilizers or solubilizers, isotonic agents, pH adjusters Stabilizers, propellants, adhesives, wetting agents, and the like can be used. In addition, other physiologically active ingredients (for example, button skin, seisei, carrot, litchi, wolfberry, etc.) may be added. By using these additives in appropriate combinations, the therapeutic agent for anemia of the present invention can have various additional functions.

  Specific examples of the excipient include starch, corn starch, sucrose, lactose, mannitol, carboxymethylcellulose, and inorganic salts.

  Examples of the disintegrant or disintegration aid include wheat starch, rice starch, corn starch, potato starch, partially pregelatinized starch, hydroxypropyl starch, sodium carboxymethyl starch, tragacanth, crystalline cellulose, methylcellulose, low-substituted hydroxypropylcellulose, Specific examples include carmellose, carmellose calcium, carmellose sodium, and croscarmellose sodium.

  Examples of the binder include agar, gelatin, wheat starch, rice starch, corn starch, potato starch, dextrin, pregelatinized starch, partially pregelatinized starch, hydroxypropyl starch, crystalline cellulose, crystalline cellulose / carmellose sodium, methylcellulose, hydroxy Propylcellulose, low substituted hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, carmellose sodium, ethylcellulose, carboxymethylethylcellulose, hydroxyethylcellulose, pullulan, polyvinylpyrrolidone, aminoalkyl methacrylate copolymer, methacrylic Copolymers, polyvinyl acetal diethylamino acetate, polyvinyl alcohol, gum arabic, gum arabic powder, white shellac, tragacanth, purified sucrose, macrogol specific examples.

  Examples of the lubricant include wheat starch, rice starch, corn starch, sucrose fatty acid ester, stearic acid, calcium stearate, magnesium stearate, hydrous silicon dioxide, light anhydrous silicic acid, synthetic aluminum silicate, and dry aluminum hydroxide gel. Specific examples include talc, magnesium aluminate metasilicate, calcium hydrogen phosphate, anhydrous calcium hydrogen phosphate, waxes, hydrogenated oil, and polyethylene glycol.

  Examples of the surfactant include sucrose fatty acid ester, soybean lecithin, polyoxyl stearate, polyoxyethylene hydrogenated castor oil, polyoxyethylene polyoxypropylene glycol, sorbitan sesquioleate, sorbitan trioleate, sorbitan monostearate, mono Specific examples include glyceryl stearate, sorbitan monopalmitate, sorbitan monolaurate, polysorbate, sodium lauryl sulfate, and lauromacrogol.

  Moreover, the anemia therapeutic agent of this invention can be designed so that an active ingredient may be sustainedly released as needed. It can also be designed so that the active ingredient is released intensively at the required location in the body. Such sustained-release preparations and drug delivery systems can be designed and manufactured according to methods well known in the pharmaceutical industry.

  In addition, an organic or inorganic carrier can be used for the anemia treatment agent of the present invention. Examples of such carriers include lactose, starch, vegetable and animal fats and oils. In the therapeutic agent for anemia of the present invention, an active substance derived from elm flower parts and leaves of urushi can be used within a range of 0.01 to 100% by weight.

  When administering the therapeutic agent for anemia of the present invention, the component derived from the elm flower part and the component derived from the leaf part of the urushi do not necessarily have to be administered simultaneously. For example, the component derived from the elm flower part may be administered first, and the component derived from the leaf part of the urushi may be administered later, or vice versa. Preferred is when administered simultaneously. In addition, the anemia treatment agent of the present invention may be of a type in which a component derived from the elm flower part and a component derived from the leaf part of the sea urchin are contained in separate containers and mixed at the time of use. . For this reason, in this invention, (1) Elm flower part or its extract and (2) Urushi leaf part or its extract are contained in either of the some composition which comprises a kit. A pharmaceutical kit for treating anemia characterized by the following:

  Component (1) and component (2) may be contained in any of a plurality of compositions constituting the pharmaceutical kit of the present invention. For example, it may be a kit comprising a composition comprising component (1) and a composition comprising component (2), or a kit comprising a plurality of compositions having different abundance ratios of component (1) and component (2). It may be. When used, these compositions may be administered as they are or in appropriate combinations.

  The administration target can be a mammal other than a human, such as a dog, or a human. The dose of the therapeutic agent for anemia of the present invention is appropriately determined according to various conditions such as the purpose of treatment or prevention, the sex, weight, age, type and degree of disease, dosage form, administration route, number of administrations, etc. . For example, in the case of oral administration, it can be administered at a dose of 0.1 μg to 100 mg (dry weight of active ingredient) / kg body weight / day once to several times a day. It is not limited.

The anemia therapeutic agent of the present invention is not necessarily in the form of a pharmaceutical product. For example, the therapeutic agent for anemia of the present invention can be used safely and effectively as a functional food or a functional beverage by including it in various foods or beverages. In particular, it can be effectively used as a food or beverage displaying the effect of improving anemia.
Specifically, it can be used for black tea, soft drinks, juices, candy, starchy foods, various processed foods, etc., but the form of use is not limited to these specific examples. The amount of the active substance derived from the elm flower part and the leaf part of the urushi can be set within a range of about 0.1 to 99% by weight. Moreover, you may improve food texture by adding a gelatinizer etc. as needed.

  Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples. The components, ratios, operation order, and the like shown in the following examples can be appropriately changed without departing from the gist of the present invention. Therefore, the scope of the present invention is not limited to the specific examples shown in the following examples.

Example 1
In this example, a specific example of the anemia treatment agent (solution) of the present invention is illustrated.
Flower buds of Vegeta, Commelin and Groenveid belonging to Ulmus hollandica were collected in March in Amsterdam, the Netherlands. The collected soot was pulverized using a mixer and dried at 110 to 120 ° C. until the water content became 1 to 5%. The obtained dry powder was sealed with an oxygen scavenger and stored at room temperature.

  The urushi young leaves were collected in March in Ishikawa Prefecture, pulverized using a mixer, and then dried at 110 to 120 ° C. until the water content became 1 to 5%. The obtained dry powder was sealed with an oxygen scavenger and stored at room temperature.

  Each dry powder was stored for 1 week, and then 7.5 g of elm dry powder and 7.5 g of urushi dry powder were mixed. To the mixed powder, 100 ml of 70% ethanol was added, stirred for 5 hours, and concentrated so that the solid content was 58% (weight). The concentrate was dissolved in physiological saline to obtain the solution of the present invention having concentrations of 5%, 10%, 15% and 20%.

(Example 2)
In this example, a specific example of the anemia treatment agent (powder) of the present invention is illustrated.
The dry powder of the elm flower part obtained in Example 1, the dry powder of young urushi leaves, and starch were mixed in the amounts shown in the following table, respectively. Thereby, the mixed powder of the present invention was obtained.

(Example 3)
In this example, specific examples of the anemia treatment agent (capsule) of the present invention are illustrated.
The capsule of the present invention was manufactured by filling the powder prepared in Example 2 into a gelatin capsule.

Example 4
In this example, specific examples of the anemia treatment agent (injection) of the present invention are illustrated.
The dry powder of elm flower part obtained in Example 1 was mixed with 7.5 g of dry powder of young urushi leaves. The mixed powder was extracted with water at 80 ° C., and the solvent was distilled off under reduced pressure. The obtained extract was dissolved in distilled water together with sodium chloride. The dry powder, sodium chloride and distilled water were mixed in the amounts shown in the following table. The injection solution of the present invention was produced by filtering the obtained aqueous solution.

(Example 5)
In a present Example, the specific example of the anemia therapeutic agent (functional drink) of this invention is illustrated.
The dry powder of elm flower part obtained in Example 1 was mixed with 7.5 g of dry powder of young urushi leaves. The mixed powder was extracted with water at 60 ° C., and the obtained extract was concentrated until the solid content weight became 10%. Then, it mixed with the following components and the ratio shown in the following table | surfaces. Thereby, the functional beverage of the present invention was obtained.

(Test Example 1)
In this test example, the anemia ameliorating action of the anemia treatment agent obtained in Example 1 on adult dogs was examined.
3 ml of the 15% solution prepared in Example 1 was orally administered once a day for one month to adult anemia dogs (35 kg body weight, Pittsburgh, female). The diet before and after administration was the same. The following table shows the blood test results before administration and after 1 month administration.

(Test Example 2)
An adult anemia (body weight 30 kg, Mel cheese, male) was orally administered with 3 ml of the 15% solution prepared in Example 1 three times a day for one month. The diet before and after administration was the same. When the blood test before administration and after one month administration was performed like Test Example 1, the results shown in the following table were obtained.

(Test Example 3)
The anemia dog (body weight 23 kg, Dalmatian, male) was orally administered with 3 ml of the 10% concentration solution prepared in Example 1 three times a day for one month, and then the 15% concentration prepared in Example 1 3 ml of the above solution was orally administered three times a day for another month. The diet before and after administration was the same. As in Test Example 1, blood tests before administration, after 1 month administration, and after 2 months administration were performed, and the results shown in the following table were obtained.

(Test Example 4)
An anemia dog (body weight 15 kg, Creole, male) was orally administered with 3 ml of the 15% solution prepared in Example 1 three times a day for one month. The diet before and after administration was the same. A blood test before administration and after 1 month administration was conducted in the same manner as in Test Example 1. As a result, an improvement effect was observed in all of the red blood cell count, hemoglobin count, and blood cell volume.

(Test Example 5)
To an anemia adult dog (body weight 50 kg, Greatden, female), 3 ml of the 10% solution prepared in Example 1 was orally administered 3 times a day for 1 month. The diet before and after administration was the same. A blood test before administration and after 1 month administration was conducted in the same manner as in Test Example 1. As a result, an improvement effect was observed in all of the red blood cell count, hemoglobin count, and blood cell volume.

(Test Example 6)
The liquid preparation prepared in Example 1 was orally administered to seven adult dogs (weight 20 to 55 kg, 5 to 7 years old, Melcheese Harder, Dalmation, Great Den, and hybrid) several times a day. An adult dog administered with 3 ml of the 15% concentration solution prepared in Example 1 3 times a day for 33 to 44 days, 3 ml of the 10% to 20% concentration solution prepared in Example 1 twice a day Both adult dogs administered over 95 to 115 days and adult dogs administered with the 10% solution prepared in Example 1 3 ml twice a day for 33 days have good appetite and physical condition, depending on the administration No adverse effects were found.

(Test Example 7)
In this test example, the composition of the solution obtained in Example 1 was examined. The results are shown in Table 7 below. In Table 7,% RDA represents the food safety regulation value (allowable limit value) in humans.

  From Table 7, as long as the composition was examined, it was found that the liquid obtained in Example 1 had no adverse effects on the human body.

  The composition of the present invention comprising an elm flower part or an extract thereof and a leaf part of an urushi or an extract thereof has an anemia improving action. Moreover, the composition of this invention can be manufactured by a simple method, and its toxicity is low. Therefore, the composition of the present invention is useful as an anemia treatment agent.

Claims (6)

  A therapeutic agent for anemia comprising an elm flower part or an extract thereof and a leaf part of an urushi or an extract thereof.   2. The anemia treatment agent according to claim 1, wherein the elm belongs to Ulmus hollandica.   Elm is selected from the group consisting of Vegeta, Comelin, Groenveid, Belgica, Crusius, Columella, Dodoens and Homestead. The anemia therapeutic agent of Claim 2 characterized by these.   4. The anemia treatment agent according to claim 3, wherein the elm is selected from the group consisting of Vegeta, Comelin, and Groenveid.   The anemia treatment agent according to any one of claims 1 to 4, comprising a powder obtained by drying elm flower parts and a powder obtained by drying leaf parts of urushi.   The anemia treatment agent according to any one of claims 1 to 4, comprising an extract of an elm flower part and an extract of a leaf part of urushi.